Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82Susana S. Najera, Jordan L. Meier|Molecular Cancer Therapeutics|2024Cited by 8